Clifton Park Capital Management’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Clifton Park Capital Management’s Portfolio CADX Stock Details CADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-1,700,000	Closed	-$15.4M	–	22
2013 Q4	$15.4M	Hold	1,700,000	–	–	0.89%	21
2013 Q3	$10.7M	Hold	1,700,000	–	–	0.64%	22
2013 Q2	$11.6M	Buy	+1,700,000	New	+$11.8M	0.69%	23

Other funds holding CADX

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Clifton Park Capital Management's CADX Position: Q1 2014 in Review

Clifton Park Capital Management sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 1,700,000 shares — an estimated $15.4M sold.

Clifton Park Capital Management first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $15.4M in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

Clifton Park Capital Management reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
Clifton Park Capital Management sold 1,700,000 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $15.4M.
Clifton Park Capital Management first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
Clifton Park Capital Management's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $15.4M in Q4 2013.
3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Clifton Park Capital Management's 13F filing for Q1 2014, filed 7 May 2014.